Powered by Blogger.

Tuesday, 25 October 2016

Kaposi Sarcoma Market expanding at a 2.6% CAGR from 2016 to 2024

The global market for Kaposi sarcoma is projected to expand at a modest 2.2% CAGR from 2016 to 2024, with the opportunity in the market rising from US$118.5 mn in 2015 to be worth US$143.2 mn by the end of the forecast period. Hospitals formed the leading distribution channel in 2015, generating over US$40 mn revenue that year. The segment is also slated emerge as the fastest growing segment in the KS market, expanding at a 2.6% CAGR from 2016 to 2024.

The global Kaposi sarcoma (KS) market is immensely consolidated and the top two players, namely Johnson & Johnson and Merck & Co. Inc. accounted for almost 50% of the overall market in 2015. The contribution of domestic players such as Sun Pharmaceutical Industries Limited is presented low. However, Transparency Market Research predicts that the contribution of these companies will increase during the forecast period owing to the patent expiry of several major drugs.

Partnerships, acquisitions, and collaborations with other leading companies for the development of newer products with improved efficacy are part of the growth strategies adopted by a number of players in the Kaposi sarcoma market. For instance, F. Hoffmann-La Roche Ltd launched a new Global Access Program in September 2014 in partnership with the Joint United Nations Program on HIV/AIDS, the President’s Emergency Plan for AIDS Relief, the Clinton Health Access Initiative, and the Global Fund. The program was centered on HIV viral load testing.

High Incidence of HIV/AIDS, Organ Transplants Driving Growth of KS Market 

Increased organ transplant procedures are a leading factor driving the Kaposi sarcoma market since the incidence of the cancer is high among patients who have undergone an organ transplant. “Organ transplant patients are given immunosuppressive agents to prevent their body from rejecting the graft. This makes them highly susceptible to Kaposi sarcoma associated herpesvirus (KSHV) infection,” the author of the study explains. The long term use of these agents increases the rate of risk of these patients by more than 100 times compared to the general population.

The high incidence of HIV/AIDS associated Kaposi sarcoma is one of the major factors driving the adoption of HAART therapy, which subsequently fuels the overall KS market.

High Cost of Treatment a Major Drawback 

The cost of cancer drugs used for the treatment of Kaposi sarcoma has been on the rise in the past few years, making it difficult for patients to seek treatment. This is a major concern for both the patients and the payers. “The prices of patented drugs have increased by over five times in the past few years in the U.S. and continue to rise,” the TMR analyst comments. For instance, prices of major drugs used for the treatment of KS, such as liposomal doxorubicin, liposomal daunorubicin, or paclitaxel in combination with HAART, have been increasing significantly, making these unaffordable for middle and lower income groups.

Slow but Steady Growth in Store for Kaposi Sarcoma Market 

By type of treatment, HAART led the overall Kaposi sarcoma market in terms of revenue, with chemotherapy and immunotherapy poised to register the highest growth rate over the coming years. In terms of region, the global Kaposi sarcoma market was led by North America in 2015 and the MEA region will record the fastest growth by 2024.

Browse Research Report on Global Kaposi Sarcoma Market:

Friday, 21 October 2016

Lifestyle Changes Resulting in High Infertility Rates to Propel Global Human Reproductive Technologies Market

A recent report on the global human reproductive technologies market has been published by Transparency Market Research. The report, titled “Human Reproductive Technologies Market - Global Industry Analysis, Size, Procedures, Growth, Trends and Forecast, 2013 - 2019,” projects this market to expand at a CAGR of 2.20% during the period from 2013 to 2019. The market is estimated to stand at a valuation of US$27.1 bn by 2019.According to the World Health Organization, in 2010, about 1.9% of the female population worldwide in the age group of 20-44 years was unable to conceive the first child. The growing prevalence of infertility has been attributed to a number of environmental and socio-economic factors. The various human reproductive technologies have witnessed increasing popularity in the past couple of years for the treatment of infertility among both men and women.

Request a PDF Brochure with Report Analysis:
With the rise in female employment, there has been a growing trend of a delay in conception. Factors such as pollution, smoking, stress, and obesity have led to an increase in infertile population. The growing prevalence of unwanted pregnancies, initiatives taken by governments and NGOs to promote contraceptive products, and the implementation of favorable policies such as the Affordable Care Act has propelled the growth of the global human reproductive technologies market.

However, limited insurance coverage and the side effects of contraceptive drugs and devices might hamper the growth of the market during the forecast period. The global human reproductive technologies market has a significant opportunity to grow with the rise in medical tourism, government support for the treatment of infertility, and the presence of a strong pipeline of contraceptive drugs.

The market for contraceptives stood at a valuation of US$16 bn in 2012. During the forecast period, the market is estimated to expand at a CAGR of 5.5%. In 2012, the oral contraceptives segment witnessed the highest demand due to the availability of contraceptives as an over-the-counter drug.

The key regions in the global human reproductive technologies market are Europe, Asia Pacific, North America, and Rest of the World. In 2012, North America emerged as the leading region in the market, followed by Europe. North America is predicted to dominate the market throughout the forecast period. However, the market is projected to register the fastest growth in Asia Pacific due to the increasing awareness about contraceptives, high population density, and rise in disposable income.

Some of the major players in the global human reproductive technologies market are Bayer AG, Abbott Laboratories, Actavis Inc., Boston Scientific Corporation, Church & Dwight Co. Inc., Merck KGaA, Warner Chilcott plc, Reckitt Benckiser Group plc, Merck Serono, Pfizer Inc., Johnson & Johnson, Cook Medical Inc., and Teva Pharmaceutical Industries Ltd. The report discusses some of the key attributes of the market players including their business strategies, product portfolio, and recent developments. Through a SWOT analysis, the report identifies the future growth opportunities for the market vendors.

Browse Research Report on Global Human Reproductive Technologies Market:

Thursday, 20 October 2016

North America Nitinol Medical Devices Market Revenue for Final Medical Components

Transparency Market Research as announced the publication of a new research report that examines the global nitinol medical devices market in great depth. The research report, titled “Nitinol Medical Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,” offers an evaluation of the strengths, weaknesses, opportunities, and threats in the market with the help of a SWOT analysis and assesses the threat of new entrants, threat of substitute products or services, bargaining power of customers (buyers), bargaining power of suppliers, and intensity of competitive rivalry with Porter’s five forces analysis.

Get Sample Research Report with ToC:
According to the research report, the global nitinol medical devices market for semi-finished goods was worth US$1.5 bn in 2012 and is expected to register a remarkable compounded annual growth rate of 7.30% to reach a valuation of US$2.5 bn by 2019. On the other hand, the global nitinol medical devices market for final medical components was worth US$8.2 bn in 2012 and is expected to register a CAGR of 11.10% to reach US$17.3 bn by the end of 2019.

In the past few years, the number of vascular disorders, such as carotid artery disease, venous disease, renal artery disease, abdominal aortic aneurysm, peripheral artery disease, and stroke have witnessed an unfortunate rise. The underlying current for this trend is the growing number of obese people and the subsequent demand for invasive surgery techniques, which has led to the growth of the global nitinol medical devices market. As this situation continues, the growth in the demand for nitinol medical equipment will also continue. Additionally, acceptance of nitinol medical equipment and a rise in the manufacture of various medical devices that use nitinol is also expected to propel the growth of this market in the near future.

The global nitinol medical devices market is segmented on the basis of type, components, and geography. The types of nitinol medical devices in the market are: semi-finished raw material and final medical components. The semi-finished raw material segment is further sub-segmented into tubes, wiring, and others such as ribbons and sheets. The final medical components segment is further divided into stents, guidewires, and others. Geographically, this market is segmented into North America, Europe, Asia Pacific, and Rest of the World.

In terms of regions, North America dominated the nitinol medical devices market in 2012. However, analysts predict that the Asia Pacific market for nitinol medical devices will grow at a rapid pace in the next three years. Furthermore, amongst the types of devices, the wiring sub-segment is expected have a CAGR of 8.2% from 2013 to 2019, while the stents sub-segment is estimated to leap forward at a pace of 13.20% CAGR in the same time frame.

Some of the important players profiled in the global nitinol medical devices market are Nitinol Devices & Components, Inc., Custom Wire Technologies, Inc., Boston Scientific Corporation, Abbott Laboratories, Inc., Cook Medical, Inc., and C.R. Bard, Inc. The research report also explains the competitive landscape in complete detail and shares important statistics pertaining to the financial overview, research and development activities, investment outlook, strategic mergers and acquisitions, and business and marketing strategies for the near future.

Browse Research Report on Global Nitinol Medical Devices Market:

Wednesday, 19 October 2016

Cell and Tissue Analysis Products Market - Global Industry Analysis and Forecast 2016 - 2024

Cell and Tissue Analysis Products Market: Overview 

Great strides made in the cell and tissue analysis products market have revolutionized many aspects of modern healthcare and treatments, noteworthy among which are diagnosis of different types of cancer, and autoimmune diseases. Cell and tissue analysis products find takers in industries, namely pharmaceutical, biotechnology, and research. They have a wide variety of uses stem cell research, drug discovery and development, cell biology, and other research practices. 

The report provides helpful insights into the cell and tissue analysis products market after thorough research. From a basic definition of cell and tissues and what cell and tissue analysis entails to the more sophisticated SWOT analysis, bringing to the fore strengths, weaknesses, opportunities, and threats influencing the segments of the global market – the report covers everything. It also provides distinctive graphics and segments the market based on geography. Additionally, it also uses a Porter’s five forces analysis that helps in determining the threat of new entrants, bargaining power of buyers and suppliers, and the intensity of the competitive rivalry. 

Further, the report delves into each product segment based on underlying technologies, its current market, and growth prospects. It endeavors to keep you abreast of the changing competitive landscape by furnishing details of historical developments and current market scenario and size. The researchers combine the two to predict growth prospects of the market – a seven-year forecast of market growth pattern 

Cell and Tissue Analysis Products Market: Trends and Opportunities

Increasing medical awareness among people, government support for healthcare and growing number of diagnostic centers are the main market growth drivers for cell and tissue analysis products. Besides, increasing spend on research and development, new technologies, new product launches and rise in lifestyle associated diseases, and growing incidence of cancer, has driven demand in the market for cell and tissue analysis products. Many modern industries trying to deploy cell and tissue analysis products in their production and process leads, has also provided a fillip to the market. Increasing competition and patent expiries, however, are proving to be a drag on companies’ performances. Given the high capital requirements to start a business in the domain and advanced stage of technology, newcomers find it a difficult market to break into. 

Apart of growth drivers and restraints, the report also covers the key product segments based on their underpinning technologies. They are: bio specimen technologies that include DNA microarray and tissue microarray; cell and tissue separation products which include enzymatic dissociators, magnetic separation, laser micro dissection, and flow cytometry; and cell and tissue characterization products which comprise research antibodies, high content screening, and cell-based assays. 

Cell and Tissue Analysis Products Market: Region-wise Outlook

Geographically, the cell and tissue analysis products market has been segmented into North America, Europe, Asia Pacific, and the rest of the world. Of them, North America is the prime consumer of cell and tissue analysis products. Countries in Asia Pacific such as Japan, India, and China, are also driving up demand in the market on account proliferation of research activities in various areas such as cancer and HIV and also on account of increasing diagnostic centers to cater to their people’s rising medical awareness. The market for cell and tissue analysis products, however, is highly fragmented with the presence of many large, medium-sized and small manufacturers that supply diagnostic products. Competition is stiff, with vendors constantly trying to form partnerships to guard their market share. 

Key Players Mentioned in the Report are:

The key players operating in the global cell and tissue analysis products market are Beckman Coulter, Millipore, Thermo-fisher Scientific, Abcam, Sigma-Aldrich, and TGA Sciences. 

Browse Research Report on Cell and Tissue Analysis Products Market:

Wednesday, 12 October 2016

Malignant Neoplasm Therapeutics Market Size, Share and Industry Trends 2024

Malignant neoplasm is believed to be one of the extended conditions of neoplasm. It is a form of cancer that develops an abnormal growth of tissues usually leading to the formation of a tumor. The primary cause of this disease is understood as damaging of DNA under certain circumstances that further escalates to a stage of cancer. The very beginning of malignant neoplasm is the occurrence of abnormal patterns of growth in the tissue known as dysplasia or metaplasia.

Higher Prevalence of Malignant Neoplasm in Geriatric Population Driving the Market Growth

The global cancer incidences have increased to a considerable number over the past few decades owing to a rise in the geriatric population, increasing life expectancy and changing lifestyle. In addition, factors such as advanced cancer diagnostics and early initiation of the treatment are fuelling the global malignant neoplasm therapeutics market. Development of targeted therapies are revolutionizing the conventional concepts of cancer treatment and are likely to get higher preference in the coming years. Moreover, a higher success ratio of these latest cancer drugs compared to traditional anti-carcinogenic treatment is expected to further drive the market growth in the near future. These latest drugs are capable of countering more than one type of cancer. For example ‘imatinib’, which was first developed for treating a single type of cancer was later found effective on multiple cancer types.

Novelty in cancer treatment has significantly influenced the present treatment models. However, a complete cure for the disease is still not ascertained. Further, many of the advanced treatment models are often expensive and only available in developed regions of the world. In some case, delay in integration of the novel drugs into current treatment methods limit the options for the patient.  Other factors such as price risk and credibility of the drugs are few of the other concerns for the market.

Over the years, the subject of oncology has received paramount attention from biomedical researchers, health care experts and pharmaceutical manufacturers. Owing to a severe need for effective treatment of cancer, heavy investments are being made in further research and development of the particular subject. Many of the pharmaceutical companies such as Novartis International AG and Pfizer Inc. are introducing a range of anti-carcinogenic drugs under their brand names promising to be more efficient. The global malignant neoplasm treatment market has become increasingly competitive in the recent years with more player joining in. Currently, most drug manufacturers offer two primary cancer therapeutic programs, namely cytostatic hormonal treatments and antineoplastics. 

Malignant Neoplasm Therapeutics Market: Regional Segmentation

On the basis of region, the global malignant neoplasm therapeutics market has been segmented into six key regions namely North America, Western Europe, Eastern Europe, Asia Pacific (APAC), Latin America, and the Middle East & Africa. North America is considered as one of the largest market of malignant neoplasm therapeutics owing to a strong presence of drug manufacturers in the region and availability of advanced healthcare facilities. In terms of value, the U.S accounts for a healthy portion of the global malignant neoplasm therapeutics market attributed to the growing demand for cancer treatment in the country. In addition, Europe is one of the other regions where the market is growing at a considerable rate and is expected to continue a similar in trend in the coming years. 

Key Players

Few of the key players identified in the global malignant neoplasm therapeutics market include F. Hoffmann-La Roche AG, Novartis International AG, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Takeda Pharmaceutical Company Ltd, Pfizer Inc. Bayer AG, Amgen, AbbVie Inc and Celgene Corporation.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Browse Research Report on Global Malignant Neoplasm Therapeutics Market:

Monday, 10 October 2016

Medical Measurement Solutions Market Global Industry Trends and Forecast 2024

Measurement Solutions for the Medical Device Industry: Overview

Revolution in the medical device industry has fully-fledged along with the demand for premium healthcare. The medical device sector covers broad range of applications with a wide variety of advanced products including dental equipment, diagnostic devices, cardiovascular devices, surgical equipment, medical equipment, ophthalmic devices, orthopedic and respiratory devices. Measurement solutions includes sensor applications & solutions, testing equipment and services, software testing solutions, instruments, equipment automation solutions etc. for the medical device industry. Predominantly prominent technological advancement in recent years includes new developments in neurology, cardiology and Health IT (e.g. Information sharing, wireless devices, systems for monitoring the cardiac activity etc.) E.g. Experts have also recycled the nanosensors technology for the rapid detection of cancers. Partnerships and acquisitions have led to new technology in biomarkers, robotic assistance, implantable electronic devices, liquid bandages/wound dressings and ingestible diagnostic devices. Measurement solutions also continues to benefit from a new procedures of nanotechnology and micro-electro-mechanical systems (MEMS).

Drivers and Restraints

Global demand for overall measurement solutions for medical devices is mainly driven by rise in healthcare expenditures and greater attention to health care by emerging markets, rise in development of hospitals and specialty clinics, and establishment of public health insurance. In addition, overall demand is growing worldwide due to aging population in major markets and increasing global income levels in developing countries. The USFDA is functioning towards increasing the number of electronic applications for approval and has published suggested rules that would require electronic reporting of post-market medical device adverse events. In recent years medical device industry is driven by innovation and the ongoing expedition for better ways of diagnosing medical hitches, future growth scenarios for this sector remain positive. Further, global management of standards and regulatory requirements may help simplify overall market growth. Measurement solutions for the medical devices are now creating an intensive market to keep patients healthier and minimize costs by neglecting unnecessary hospitalizations. This adoption is really a value based shift payment for medical device providers. 

Global Ventilators Market: Segmentation

The Global Ventilators Market market can be segmented as follows:

Global ventilator accessories market by Device Type
  • Drug Delivery Devices
  • Surgical Tools
  • Orthopedics
  • Robotic Surgery
  • Therapeutic Devices
  • Others (Sensors, Digital Software etc.) 
Global Ventilators Market, by End User
  • Hospitals
  • Ambulatory Surgery Centres
  • Clinics
  • Emergency Medical Services
  • Long term care centres
  • Home Care Settings
  • Regional Outlook
Geographically, the measurement solutions for the medical device industry is segmented into five regions, namely North America, Latin America, Europe, Asia Pacific & Middle East and Africa. North America medical device sector is expected to persist highly competitive globally. Measurement solutions for the medical device industry is an accepted, necessary component of the U.S. healthcare system. Rise in number of multinational medical device manufacturing firms are looking for regulatory approval for their products in more countries worldwide. Medical device solution providers are now more focused in expanding the product portfolio in other developing regions to drive future growth. For e.g., more demand for medical devices in Asia pacific is increasing at a higher rate compared to developed countries. In Asia pacific regions electronics and medical device industries are starting to make acquisitions, now improving the efficiency of the healthcare delivery system as well as workforce in other sectors too.

Measurement solutions for the medical devices needs a complete understanding of equipment operation, device automation, application and testing. Manufacturers are launching innovative products such as sensors, testing equipment, scanners, measurement systems or any other measurement solutions with a high degree of expertise. Measurement solution for medical devices demands more safety and quality measurement protocols. Medical device development faces specific challenges that also affect most companies these days mainly due to increased competition in sales and service in the international market, also facing issues in the durability and development of advanced automated solutions.

Browse Research Report on Global Measurement Solutions for the Medical Device Market:

Thursday, 6 October 2016

Advance Basal Cell Carcinoma Market Global Analysis and Trends in 2024

Advance basal cell carcinoma are abnormal, uncontrolled growths or lesions which appear on the skin, they arise from basal cells of the skin which are found on the inner most layer epidermis. They look like open sores, pink growths, red patches or scars which are caused due to cumulative and intense exposure to the sun. Basal cell carcinoma generally does not spread beyond the original site of the tumor, they mostly affect the head, face scalp, hand and the neck areas but spread to other parts and become malignant if not diagnosed.

Get Sample Research Report with TOC:

Basal cell carcinoma is the most common form of skin cancer which accounts for nearly 80% of all cases, if not treated may get into the advance stage. Basal cell carcinoma which infiltrates below the skin or vital organ is difficult to treat surgically. It is commonly found in elderly and fair skinned individuals. Treatment of advance basal cell carcinoma is carried out with surgical, destructive and topical therapeutic treatments. Although if not treated properly or neglected it may become aggressive or recurrent basal cell carcinoma may progress to an advanced state. The characteristics of a tumor becoming advance basal cell carcinoma may differ. The major challenges in treating advance basal cell carcinoma include its size, location, invasiveness and extent. It comprises of non-melanoma skin cells as compared to other malignancies. Individuals suffering from advance basal cell carcinoma fall under two categories, one who have advance basal cell carcinoma due to delay in accessing medical treatment and with whom basal cell carcinoma reoccur after treatment.

The treatment for advance basal cell carcinoma is quite complicated as both patients and tumor characteristics have to be taken into consideration before starting the treatment. Generally, more than one therapeutic methodology has to be taken into account for the treatment. The mortality rate for basal cell carcinoma is low as compared to other forms of malignant tumors as these rarely become malignant, these tumors are generally curable but sometimes due to reoccurrence it is hard to completely get rid.

There are many different ways to prevent basal cell carcinoma, such as by avoiding skin exposure to direct sunlight, this can be avoided by using high factor sunscreen to exposed skin if outdoors. Cases which are associated with high cost and recovery time the use of radiation therapy or hedgehog inhibitor therapy may be taken into consideration. In some cases where surgery may not be sufficient alternative medication is used which could be topical, oral or hedgehog inhibitors may be taken into consideration. In recent times newer and more effective therapeutics have been developed which include inhibitors which block the Hedgehog pathway which stops the reoccurrence of advance basal cell carcinoma. These new therapeutics would help in extending the lifespan of people who have metastatic advance basal cell carcinoma. Advance basal cell carcinoma are sometime difficult to treat and can become life threatening this is mainly due to reoccurrence rate and progressiveness of the disease.Therefore it requires constant monitoring. The American Cancer Society strongly recommends dermatologic checkup in every three years for individuals between 20-40 years of age and every year for individual above 40 years of age.

The global market for advance basal cell carcinoma is segmented into five key regions viz.  North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. The region of North America leads the market for advanced basal cell carcinoma therapeutics and is closely followed by European region. It is estimated that in coming years more people will get affected by advance basal cell carcinoma in the U.S and the U.K. In recent times the Asia-Pacific region has observed a substantial growth in advance basal cell carcinoma therapeutic market as number of people are getting affected by advance basal cell carcinoma, thus increasing the demand for therapeutics in the region.

The major factors driving the growth of the market for advance basal cell carcinoma are increasing aging population, environmental changes, increased use of immunosuppressant, increased exposure to sunlight, increased demand for new therapeutics and better reimbursement policies. The restraining factor for advance basal cell carcinoma therapeutics market is delay in accessing medical condition, lack of awareness amongst individual and cost of certain therapeutics. As technological advancements are made some therapeutic drugs are being discovered which are in clinical trials and different phases of development would help the therapeutic market for advance basal cell carcinoma to grow. Key players involved in advance basal cell carcinoma market are F. Hoffmann-La Roche Ltd., Novartis, Genentech Inc., Merck & Co. Inc., Bristol-Myers Squibb Company, Amgen Inc., Cannabis Science, INC., Curis Inc., Galderma S.A., Prime Therapeutics LLC, and Graceway Pharmaceuticals.

Browse Research Report on Global Advance Basal Cell Carcinoma Market: